Crossmark

15-strain live biotherapeutic product or same donor fecal microbiota transplant for recurrent Clostridioides difficile infection: a randomized phase 1b trial

Crossref DOI link: https://doi.org/10.1038/s41591-026-04442-2

Published Online: 2026-06-02

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Bethlehem, Lukas

Bartu, Lorenza

Marke, Gina

Mar, Phyu

Feldman, Sari

Eggers, Joseph

Ruprecht, Constantin

Britton, Graham J. https://orcid.org/0000-0003-4630-1223
Aggarwala, Varun https://orcid.org/0000-0002-5499-7745
Bongers, Gerold

Li, Zhihua

Yang, Nancy

Hohmann, Elizabeth L.

Mogno, Ilaria

Faith, Jeremiah J. https://orcid.org/0000-0002-2691-4500
Grinspan, Ari https://orcid.org/0000-0002-0719-1538
License Information

Text and Data Mining valid from 2026-06-02

Version of Record valid from 2026-06-02
More Information

Article History

Received: 11 September 2025

Accepted: 1 May 2026

First Online: 2 June 2026

Competing interests

: J.J.F. is on the scientific advisory board of Vedanta Biosciences, reports receiving research grants from Janssen Pharmaceuticals and reports receiving consulting fees from GENFIT and Vedanta Biosciences. A patent is filed on MTC01 (J.J.F., L. Bethlehem, J.E. and V.A.). The other authors declare no competing interests.

Document is current

Any future updates will be listed below